The drugmaker reported strong revenue and earnings growth thanks largely to solid growth for narcolepsy drug Xyrem.
News & Analysis: Jazz Pharmaceuticals
JAZZ earnings call for the period ending March 31, 2019.
How many have you heard of? And what can we learn from their strong performances?
JAZZ earnings call for the period ending December 31, 2018.
They're all dirt cheap. And they're all poised to generate solid returns over the long run.
These biotech and pharma stocks are valued at or below eight times next year's profit projections.
A biotech ETF, a cash-gushing large-cap, and a dirt-cheap biopharma company top our list of great stocks to buy right now.
Jazz's third-quarter earnings missed the mark, causing some investors to hit the exits today.
Looking for a few timely buys in the biotech space? Give these gems a closer look.
Looking for value in today's pricy market? These three stocks fit the bill.